Study of IL-17 Inhibitors for Treating Hidden Enthesitis in Adults With Moderate to Severe Psoriasis Using Ultrasound

What this Trial Is About

This research investigates the effects of IL-17 inhibitors on subclinical enthesitis in adults with moderate to severe psoriasis. The study is observational, prospective, and open-label, aiming to assess the safety and effectiveness of these inhibitors using Power Doppler Ultrasonography PDUS to detect enthesitis. It focuses on patients with inflammatory changes at peripheral attachment points, which are not yet clinically apparent. Participants will receive IL-17 inhibitor treatment as part of routine care, with study evaluations occurring over a 52-week period. The primary outcome is the change in the Glasgow Ultrasound Enthesitis Scoring System GUESS from baseline to week 24. Secondary outcomes include changes in GUESS at various time points, resolution of enthesitis, bone changes, skin assessments, pain scores, and progression to psoriatic arthritis. Throughout the study, participants will undergo ultrasound assessments and clinical evaluations at multiple visits up to week 52. Researchers will monitor skin and joint symptoms, pain levels, and structural changes using various scoring tools. Safety and treatment effects will be tracked prospectively, with participant involvement lasting approximately one year.

A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS)